CDSCO panel nod to Sun Pharma to manufacture, market antidiabetic FDC drug
Advertisement
In a significant development, pharmaceutical major, Sun Pharma has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture and market the popular anti-diabetic fixed dose combination (FDC) drug comprising Dapagliflozin Propanediol Monohydrate, Sitagliptin, and Metformin Hydrochloride.
This came after the company presented the committee with the clinical report (CT) of the FDC Dapagliflozin Propanediol plus Sitagliptin plus Metformin Hydrochloride tablets.
For more details, check out the link given below:
Sun Pharma Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Drug
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.